A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib

Mehmet Artaç, Levent Korkmaz, Mustafa Karaağaç, Buğra Kaya, Necdet Poyraz, Hakan Öзон, Zehra Era, Lema Tavlı

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib

Mehmet Artaç, Levent Korkmaz, Mustafa Karaağaç, Buğra Kaya, Necdet Poyraz, Hakan Öзон, Zehra Era, Lema Tavlı

1. Introduction

Sensitizing EGFR mutations were seen in near 10% of Caucasian patients with non-small lung cancer (NSCLC) and up to 50% of Asian patients. The echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) gene rearrangements occur up to 7% of patients with NSCLC. In a study, 1.6% of 380 patients showed both EGFR and EML4-ALK mutations. These mutations showed predictivity for response to specific tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib, or afatinib) for the cases with EGFR mutations and crizotinib, alectinib, and ceritinib for the patients who have EML4/ALK translocation. Both EGFR and EML4/ALK mutations were reported in only four cases of 1458 lung cancer patients. In that report, ALK inhibitors appeared to be more effective for cases with co-mutations. The exon 18-EGFR mutations were demonstrated in 2.8% of lung adenocarcinomas. Single exon 18-EGFR mutation caused a worse survival than multiple EGFR exon of 18 mutations.

In this case presentation, a case of harboring EML4/ALK rearranged lung adenocarcinoma who previously had an EGFR mutation in exon 18 and received erlotinib. A partial tumor response was achieved with crizotinib after failure with erlotinib therapy and chemotherapy. We conclude that it is important to evaluate for EML4/ALK rearrangement even the patient has EGFR mutation. Concomitant EGFR exon 18 and EML4-ALK mutations can occur in lung adenocarcinoma. EML4/ALK related TKIs may be more effective in these patients.

© 2018 Turkish Society of Medical Oncology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
detected in the tumor tissue (Fig. 1C). Due to detection of EGFR mutation ALK gene rearrangement was not studied at that time. Then erlotinib was started. After four months of erlotinib, brain metastasis occurred. Thus, the patient underwent 8 cycles of pemetrexed. Due to the development of atelectasis in left lung, palliative radiotherapy was performed. And then the patient was administrated nine cycles of gemcitabine. Progression was seen in lung and abdominal CT with a new lesion in the liver (Fig. 1B). Biopsy was performed from the new liver lesion for assessing EML4/ALK rearrangement in May 2013 (Fig. 1A). Fluorescence in situ hybridization technique showed ALK gene rearrangement. Thus crizotinib was administrated. PET CT scan showed regression in bone and liver lesions (Fig. 1D). In January 2015, progression of the brain lesion was seen in brain magnetic resonance imaging. Radiotherapy was performed to brain lesion. Then paclitaxel plus carboplatin combination was administrated concurrent with crizotinib. After receiving three cycles of chemotherapy, treatment was discontinued due to worsening in performance status. After 6 months of drug-free follow up, increase in tumor size was demonstrated with chest CT scan. Then nivolumab was started. After one cycles of nivolumab the patient died.

3. Discussion

Concomitant EGFR and EML4/ALK alterations are seen rarely in lung adenocarcinoma. This phenomenon can, in fact, be explained by the concept of tumor heterogeneity according to which different mutations of tyrosine kinase receptors might coexist. In our case biopsy from liver metastasis demonstrated the EML4/ALK rearrangement. We detected EGFR mutation in the primary tumor and ALK rearrangement in the liver metastases. This can show the importance of biopsies from the new metastatic sites, when it is possible. The probability of coexistence of ALK fusions and EGFR mutations should be kept in mind to treat these patients with each way.

Today, TKIs are effective therapies for lung cancer patients. Thus, detection of specific mutations in tumor is very important. Albeit rare, in present case we detected concomitant EGFR exon 18 mutation and EML4/ALK rearrangement. Although the patient had received erlotinib, brain metastases occurred after four months. This EGFR exon 18 mutation is a rare mutation and this patient did not benefit from EGFR TKI. The recent literature revealed that EGFR exon 18 mutations had a worse survival outcome than the other EGFR mutations.8 However, the efficacy of crizotinib was remarkable with 19 months of progression-free. EML4/ALK rearrangement detection is clinically important and associated with marked crizotinib sensitivity. In early trials of crizotinib, the rate of objective response was 60% and median progression free survival was found up to 10 months in NSCLC patients.9,10

4. Conclusion

Detection of mutations in new metastatic sites could be very important. Concomitant EGFR exon 18 and EML4-ALK mutations can occur in lung adenocarcinoma. EML4/ALK related TKIs may be more effective in these patients.
References


